Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.

Iqbal J, Wu HX, Hu N, Zhou YH, Li L, Xiao F, Wang T, Jiang HL, Xu SN, Huang BL, Zhou HD

Obesity reviews : an official journal of the International Association for the Study of Obesity22 Feb 2022Cited by 140 (Europe PMC)

PMID35194917DOI10.1111/obr.13435PepBankPUB-35194917

Publisher page PubMedAsk about this study

Jump to 28 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study28

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with obesity without diabetes, a subgroup analysis showed a greater weight loss effect with semaglutide than with liraglutide.
In plain wordsIn adults with obesity without diabetes, semaglutide led to more weight loss than liraglutide in a subgroup analysis.
Peptide
Semaglutide
Outcome
DecreaseWeight loss effect, semaglutide versus liraglutide
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis showed greater treatment effect of semaglutide than liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
Report a problemFND-3519491701
02HumanSystematic reviewEfficacy outcome
In adults with obesity without diabetes, a subgroup analysis showed a smaller weight loss effect with liraglutide than with semaglutide.
In plain wordsIn adults with obesity without diabetes, liraglutide led to less weight loss than semaglutide in a subgroup analysis.
Peptide
Liraglutide
Outcome
Not applicableWeight loss effect, liraglutide versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analysis showed greater treatment effect of semaglutide than liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
Report a problemFND-3519491702

Studies that did not test the peptide alone26

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA caused more weight loss than control, with a mean difference of -7.1 kg.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group caused more weight loss than control.
Peptide
Semaglutide
Outcome
DecreaseBody weight, pooled GLP-1 RA versus control
Study
n = 11,459
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
−7.1 kg
GLP-1 RA vs control
Source sentences
Summary
Compared with control groups, a more significant weight loss was seen in GLP-1 RA groups with an overall mean difference of -7.1 kg (95% CI -9.2 to -5.0) (I² = 99%).
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491703
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA caused more weight loss than control, with a mean difference of -7.1 kg.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group caused more weight loss than control.
Peptide
Liraglutide
Outcome
DecreaseBody weight, pooled GLP-1 RA versus control
Study
n = 11,459
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
−7.1 kg
GLP-1 RA vs control
Source sentences
Summary
Compared with control groups, a more significant weight loss was seen in GLP-1 RA groups with an overall mean difference of -7.1 kg (95% CI -9.2 to -5.0) (I² = 99%).
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491704
05HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA improved glycemic control.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group improved blood sugar control.
Peptide
Semaglutide
Outcome
DecreaseGlycemic control, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The overall analysis results showed that GLP-1 RA improved glycemic control without increasing the risk of hypoglycemic events.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491705
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA improved glycemic control.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group improved blood sugar control.
Peptide
Liraglutide
Outcome
DecreaseGlycemic control, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The overall analysis results showed that GLP-1 RA improved glycemic control without increasing the risk of hypoglycemic events.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491706
07HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, pooled GLP-1 RA did not increase the risk of hypoglycemic events.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group did not raise the risk of low blood sugar.
Peptide
Semaglutide
Outcome
No significant changeHypoglycemic events, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
The overall analysis results showed that GLP-1 RA improved glycemic control without increasing the risk of hypoglycemic events.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491707
08HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, pooled GLP-1 RA did not increase the risk of hypoglycemic events.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group did not raise the risk of low blood sugar.
Peptide
Liraglutide
Outcome
No significant changeHypoglycemic events, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
The overall analysis results showed that GLP-1 RA improved glycemic control without increasing the risk of hypoglycemic events.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491708
09HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA treatment gave better blood pressure control.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group were linked to better blood pressure control.
Peptide
Semaglutide
Outcome
DecreaseBlood pressure, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Better control of blood pressure and plasma levels of LDL, HDL, and triglycerides was seen with GLP-1 RA treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491709
10HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA treatment gave better blood pressure control.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group were linked to better blood pressure control.
Peptide
Liraglutide
Outcome
DecreaseBlood pressure, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Better control of blood pressure and plasma levels of LDL, HDL, and triglycerides was seen with GLP-1 RA treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491710
11HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA treatment gave better control of LDL.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group were linked to better LDL cholesterol control.
Peptide
Semaglutide
Outcome
DecreaseLDL cholesterol, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Better control of blood pressure and plasma levels of LDL, HDL, and triglycerides was seen with GLP-1 RA treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491711
12HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA treatment gave better control of LDL.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group were linked to better LDL cholesterol control.
Peptide
Liraglutide
Outcome
DecreaseLDL cholesterol, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Better control of blood pressure and plasma levels of LDL, HDL, and triglycerides was seen with GLP-1 RA treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491712
13HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA treatment gave better control of HDL.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group were linked to better HDL cholesterol control.
Peptide
Semaglutide
Outcome
IncreaseHDL cholesterol, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Better control of blood pressure and plasma levels of LDL, HDL, and triglycerides was seen with GLP-1 RA treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491713
14HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA treatment gave better control of HDL.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group were linked to better HDL cholesterol control.
Peptide
Liraglutide
Outcome
IncreaseHDL cholesterol, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Better control of blood pressure and plasma levels of LDL, HDL, and triglycerides was seen with GLP-1 RA treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491714
15HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA treatment gave better control of triglycerides.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group were linked to better triglyceride control.
Peptide
Semaglutide
Outcome
DecreaseTriglycerides, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Better control of blood pressure and plasma levels of LDL, HDL, and triglycerides was seen with GLP-1 RA treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491715
16HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with obesity without diabetes, pooled GLP-1 RA treatment gave better control of triglycerides.
In plain wordsIn adults with obesity without diabetes, GLP-1 drugs as a group were linked to better triglyceride control.
Peptide
Liraglutide
Outcome
DecreaseTriglycerides, pooled GLP-1 RA
Study
n: not reported in source
Comparator
Control
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Better control of blood pressure and plasma levels of LDL, HDL, and triglycerides was seen with GLP-1 RA treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491716
17HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, vomiting was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, vomiting was a common side effect of GLP-1 drugs as a group.
Peptide
Semaglutide
Outcome
Not applicableVomiting, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491717
18HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, vomiting was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, vomiting was a common side effect of GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
Not applicableVomiting, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491718
19HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, nausea was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, nausea was a common side effect of GLP-1 drugs as a group.
Peptide
Semaglutide
Outcome
Not applicableNausea, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491719
20HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, nausea was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, nausea was a common side effect of GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
Not applicableNausea, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491720
21HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, dyspepsia was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, indigestion was a common side effect of GLP-1 drugs as a group.
Peptide
Semaglutide
Outcome
Not applicableDyspepsia, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491721
22HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, dyspepsia was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, indigestion was a common side effect of GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
Not applicableDyspepsia, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491722
23HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, diarrhea was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, diarrhea was a common side effect of GLP-1 drugs as a group.
Peptide
Semaglutide
Outcome
Not applicableDiarrhea, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491723
24HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, diarrhea was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, diarrhea was a common side effect of GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
Not applicableDiarrhea, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491724
25HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, constipation was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, constipation was a common side effect of GLP-1 drugs as a group.
Peptide
Semaglutide
Outcome
Not applicableConstipation, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491725
26HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, constipation was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, constipation was a common side effect of GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
Not applicableConstipation, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491726
27HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, abdominal pain was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, belly pain was a common side effect of GLP-1 drugs as a group.
Peptide
Semaglutide
Outcome
Not applicableAbdominal pain, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3519491727
28HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In adults with obesity without diabetes, abdominal pain was a common adverse effect of pooled GLP-1 RA.
In plain wordsIn adults with obesity without diabetes, belly pain was a common side effect of GLP-1 drugs as a group.
Peptide
Liraglutide
Outcome
Not applicableAbdominal pain, pooled GLP-1 RA
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.
2 context sentences(design, population, supporting numbers)
Summary · context
We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase.
Summary · context
Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3519491728

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.

Summary

Results from this study28

Studies that did not test the peptide alone26

Version history

Subjects

Publication types

MeSH terms

Keywords